[1] DAVID G WINKLER. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.[J]. Chemistry & biology, 2013, 20 11: 1364-1374. DOI:
10.1016/j.chembiol.2013.09.017[2] SHUAI DONG. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.[J]. Blood, 2014, 124 24: 3583-3586. DOI:
10.1182/blood-2014-07-587279[3] IAN W FLINN. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.[J]. Blood, 2018, 131 8: 877-887. DOI:
10.1182/blood-2017-05-786566[4] KERRIE FAIA. The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies.[J]. ACS Applied Bio Materials, 2018: e0200725. DOI:
10.1371/journal.pone.0200725[5] RUTH J DAVIS. Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.[J]. Cancer research, 2017, 77 10: 2607-2619. DOI:
10.1158/0008-5472.can-16-2534